

March 30, 2007

## **AMICUS THERAPEUTICS FILES FOR INITIAL PUBLIC OFFERING**

Cranbury, NJ, March 30, 2007 – Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. All shares in the offering will be sold by Amicus Therapeutics.

The underwriters for the offering are led by Morgan Stanley & Co. Incorporated and Merrill Lynch & Co., as joint book-runners, with J.P. Morgan Securities Inc., Lazard Capital Markets LLC, and Pacific Growth Equities, LLC acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. When available, a preliminary prospectus may be obtained by contacting Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014, attention: Prospectus Department, or by e-mailing [prospectus@morganstanley.com](mailto:prospectus@morganstanley.com) or Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080.

### **About Amicus Therapeutics**

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase 2 clinical trials of Amigal™ for the treatment of Fabry disease and Plicera™ for the treatment of Gaucher disease. The company is currently conducting Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

### **Safe Harbor Statement**

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words “may,” “believes,” “will,” “expects,” “anticipates,” or the negation thereof, or similar expressions, which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Amicus to be materially different from any

future results, performance or achievements expressed or implied by such forward-looking statements. For those statements, Amicus claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. Amicus will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

###